Drug · DIN 02287447
EXJADE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since November 10, 2006; first marketed November 10, 2006.
- Drug Identification Number (DIN)
- 02287447
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet For Suspension
- Route
- Oral
- Therapeutic class (ATC)
- Deferasirox V03AC03
- Class
- Human
- Record last updated
- June 15, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DEFERASIROX | 500 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 17, 2022: NOC 28772Supplement to a New Drug Submission (SNDS) · To update the Product Monograph
- October 18, 2006: NOC 8332New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “exjade”. A notice may cover another product or only some lots: read it to see what it covers.
Other DINs named EXJADE
- DIN 02287420 · Marketed
- DIN 02287439 · Marketed